Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06339138 · ClinicalTrials.gov registry record
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
A clinical trial of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 589
- Enrollment target
- 1
- Study location
NCT06339138: Active study of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Mayo Clinic.
NCT06339138 is a study of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 589 participants, above the 232-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (154% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06339138, a study of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 589 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
Primary Outcome
Assessed by the number of markers identified using unbiased whole methylome sequencing (RRBS). Top candidates will be validated in independent tissue. Potential markers will have relatively low background and a false discovery rate 20%.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2027-01-31 |
What the registry record for NCT06339138 still lists
NCT06339138 is an observational study that tracks outcomes without assigning an intervention. The registered 589 participants enrollment target is mid-sized for trials with a published cap, above the 232-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (154% higher).
The record links to 6 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06339138 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06339138 about?
NCT06339138 is a clinical study titled "Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study". This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
What is the current status of trial NCT06339138?
This trial is currently active not recruiting. The enrollment target is 589 participants. The study started on 2018-06-27. Estimated completion is 2027-01-31.
What conditions does trial NCT06339138 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor.
What interventions are being tested in trial NCT06339138?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06339138?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06339138 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06339138's enrollment target sits among peer trials
589 10th of 85 higher than 76 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI